As we noticed IRS4 expression particularly in HER2+ tumours and found IRS4 to induce constitutive PI3K/AKT pathway activation, we investigated the involvement of IRS4 with regard to sensitivity to therapeutic agents. Here, ERBB2 is linked to neoplasm.